Earnings call transcript: Mirion Technologies Q2 2025 highlights revenue growth

Mirion Technologies (MIR) reported a 7.6% year-over-year increase in revenue for Q2 2025, reaching $222.9 million. The company also saw a 10% rise in adjusted EPS to $0.11 per share. Following the earnings release, Mirion’s stock showed a 1.7% increase in regular trading, closing at $24.43, though it dropped by 2.05% to $23.93 in aftermarket trading. With a market capitalization of $6.02 billion, the stock has demonstrated remarkable momentum, delivering a 40% return year-to-date according to InvestingPro data.

Key Takeaways

• Revenue grew by 7.6% year-over-year, reaching $222.9 million.
• Adjusted EPS increased by 10% to $0.11 per share.
• The company raised its full-year guidance for revenue, EBITDA, and free cash flow.
• Mirion launched several new products and acquired Survalent.
• The nuclear power market shows strong fundamentals, supporting Mirion’s growth.

Company Performance

Mirion Technologies demonstrated solid performance in Q2 2025, with revenue climbing 7.6% year-over-year to $222.9 million. This growth was driven by a 5.4% increase in organic revenue. The company also reported a 4.9% increase in adjusted EBITDA, reaching $51.2 million. Mirion’s strategic focus on innovation and market expansion, particularly in the nuclear power sector, has positioned it well against competitors. The company maintains a healthy financial position with a current ratio of 2.54, indicating strong liquidity to meet short-term obligations. InvestingPro analysis reveals 13 additional key insights about Mirion’s financial health and growth prospects.

Financial Highlights

• Revenue: $222.9 million, up 7.6% year-over-year
• Adjusted EPS: $0.11, up 10%
• Adjusted EBITDA: $51.2 million, up 4.9%
• Organic revenue growth: 5.4%

Outlook & Guidance

Mirion Technologies has raised its full-year guidance for revenue, EBITDA, and free cash flow. The company expects total revenue growth of 7-9% for 2025. Adjusted EBITDA is projected between $223 million and $233 million, with adjusted free cash flow anticipated to range from $95 million to $115 million. The company is targeting 30% EBITDA margins by 2028, driven by strong growth in the nuclear power market. Based on InvestingPro’s Fair Value analysis, the stock appears overvalued at current levels, trading near its 52-week high of $25.16. For deeper insights into Mirion’s valuation and growth prospects, access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

Executive Commentary

CEO Tom Logan highlighted the company’s growth opportunities, stating, "We are seeing sizable opportunities across the nuclear landscape." CFO Brian Schopfer reiterated the company’s commitment to achieving a 30% EBITDA margin, emphasizing, "We continue to be very committed to the 30% EBITDA margin target."

Risks and Challenges

• Supply chain disruptions could impact product delivery timelines.
• Regulatory changes in the nuclear sector may affect operations.
• Economic downturns could reduce demand for nuclear power solutions.
• Competition in the nuclear medicine and radiation therapy markets remains intense.

Q&A

During the earnings call, analysts inquired about the strategic rationale behind the Survalent acquisition and the company’s plans for margin expansion. Executives addressed these concerns, emphasizing the acquisition’s role in enhancing regulatory compliance solutions and outlining strategies to improve operational efficiencies.

Full transcript - Mirion Technologies Inc (MIR) Q2 2025:

Stacy, Conference Call Operator: Greetings and welcome to the Mirion Technologies second quarter 2025 earnings conference call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Eric Linn, Vice President of Investor Relations Group. Please go ahead.

Eric Linn, Vice President of Investor Relations, Mirion Technologies: Thank you, Stacy. Good morning and welcome to Mirion’s second quarter 2025 earnings conference call. Joining me this morning are Mirion’s Chairman and CEO Tom Logan and Mirion CFO and Medical Group President Brian Schopfer. Before we begin today’s prepared remarks, allow me to remind you that comments made during this call will include forward-looking statements and actual results may differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in our annual report on Form 10-K, quarterly reports on Form 10-Q, and Mirion’s other SEC filings under the caption Risk Factors. Quarterly references within today’s discussion are related to the second quarter ended June 30, 2025, unless otherwise noted. The comments made during this call will also include certain financial measures that were not prepared in accordance with Generally Accepted Accounting Principles.

Reconciliation of those non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the appendix of the presentation accompanying today’s call. All earnings materials can be found in the Investor Relations section of our website at www.mirion.com. With that, let me now turn the call over to Tom, who will begin on slide 3.

Tom Logan, Chairman and CEO, Mirion Technologies: Eric, thank you and a warm welcome to everyone on today’s earnings call. As always, we appreciate your interest in the company. Taking a look at our Q2 results, we demonstrated continued progress on key financial and strategic objectives, most notably increasing adjusted free cash flow generation, stepping up our M&A game and optimizing our capital structure. I’d like to thank my many Mirion colleagues for delivering another solid quarter. In addition, we’ve increased key components of our 2025 guidance based upon a bullish outlook for the second half. We’ll have more on this in a bit. Beyond quarterly results, I’ll spend some time discussing the growing momentum in the nuclear power sector, specifically how it is increasing Mirion’s opportunities across the installed base, new utility scale projects and small modular reactors or SMRs.

Regarding M&A, last night we were very pleased to announce the acquisition of Survalent, a leading provider of regulatory compliance solutions to the U.S. nuclear industry and a wider energy power market. We are incredibly excited to welcome the Survalent team on board and believe that together we can better serve the rapidly growing North American energy markets. Let’s turn to panel four to get into the details. Second quarter revenue totaled $222.9 million. This reflects a 5.4% increase in organic revenue and a 7.6% increase in total revenue versus Q2 2024. Higher revenue reflects a $2 million tailwind from our Medical segment due to shipment timing from tariff impacts and, importantly, all six end markets from both segments contributed to the growth. Second quarter adjusted EBITDA was $51.2 million, up 4.9% versus last year’s second quarter. The Medical segment was a positive contributor in the quarter.

Conversely, Nuclear and Safety segment EBITDA was negatively impacted by non-recurring items. During the quarter, we made significant improvements to our capital structure. In May, we successfully completed a $400 million convertible note offering. Later in the quarter, we refinanced our term loan B with a smaller $450 million term loan. The improved capital structure gives us the flexibility for further capital deployment and lowers our total cost of capital. Next, we generated $6 million of adjusted free cash flow in Q2, an 11% conversion of adjusted EBITDA. This, coupled with better than expected first quarter cash performance, undergirds our increased 2025 adjusted free cash flow guidance. Finally, second quarter orders grew by 1.6%. This growth was primarily from our Medical segment. Nuclear and Safety segment orders were lower in the quarter, which was not particularly surprising given the tough comp from the quarter of 2024.

As you may recall, we experienced 17% order growth in the nuclear power end market in Q2 of last year. This comp, combined with timing dynamics, resulted in lower Nuclear and Safety segment orders in Q2 2025. Despite this, we’re highly encouraged by growing engagement in the nuclear ecosystem. Year to date, we’ve booked approximately $9 million in SMR-related orders with five different players. Historically, we’ve disclosed $17 million in aggregate SMR orders and we’re pleased with the accelerating growth in this sector and continue to strengthen our position. Brian will provide more details on our quarterly performance. I’d like to use my time to provide more context around the improving dynamics within nuclear power beginning on panel five. As you’ll see later, we are increasing our 2025 organic growth expectations for the nuclear power sector. We are seeing sizable opportunities across the nuclear landscape.

While new builds and SMRs are grabbing the headlines, the installed fleet represents an improving opportunity set for the company. Recall that approximately 80% of the nuclear power end market revenue comes from this installed base and is typically accompanied with higher margins. The improving fleet opportunity comes principally in three forms: from modernization upgrades, from expanding nuclear capacity, and from extending operating lifetimes. Modernization CapEx is the greatest near-term opportunity for the company. As illustrated on the slide, nuclear operators are planning to meaningfully increase their capital budgets over the next four years, supporting a growing opportunity for Mirion. The average age today of the operating fleet is around 40 years old, based on an expected 60 to 80 year operating lifespan. The nuclear reactors are today middle aged. As a result, system upgrades and modernization are required to ensure continued safe and efficient performance.

We expect accelerating reinvestment based upon extensive customer feedback. This slide also highlights additional reinvestment opportunities within the installed base. Decisions to expand nuclear capacity, either through power uprates or higher capacity factor targets, often require incremental capital investments from customers. We are seeing our customers invest in next generation in-core and XCORE instrumentation and bring on additional monitoring to more precisely manage key operating parameters. This gives them the confidence to run at higher utilization levels. The third opportunity comes through extending operating lifetimes, including recently announced restarts. This is perhaps the largest opportunity source for Mirion. Life extensions extend the clock on a nuclear facility and drive spare parts replenishment, system upgrades, software royalties, and services to support operations for an additional 10 to 20 years. Importantly, when an operator plans on decommissioning a power plant, they typically reduce CapEx dramatically three to five years in advance.

Thus, decisions to life extend also reverse this subtle dynamic. In July, Vistra received approval from the NRC to extend operations of its Perry nuclear plant through 2046. This is the most recent example of the appetite to extend the life of existing reactors. Given all this, it should not be surprising then that we have been eager to strengthen our nuclear power related portfolio organically. We’ve been active this year introducing new products into the market as shown on panel six. Earlier this week, I hosted our 20th annual Mirion Connect event with more than 400 in attendance. This annual event brings our customers together to share ideas, showcase our latest innovations, and provide continuing education and training. It’s also a tremendous opportunity for lead generation.

This year marked record attendance as customers are eager to collaborate to solve their most pressing challenges with a far greater sense of urgency. In this vein, last week we released our VITAL platform. This is the digital ecosystem we foreshadowed in our Investor Day in December, and it’s a direct response to customer needs. VITAL helps operators to simplify monitoring, streamline operations, and improve safety by facilitating real-time monitoring and data collection from thousands of instruments and sensors. VITAL is intended to integrate seamlessly, to scale with ease, and support workflow optimization, and it replaces more than a dozen discrete supervisory software applications. It also provides a platform for our expanding digital offerings to interact on a plug and play basis. We also highlighted our LightLink technology at Mirion Connect. This technology allows for superior detection efficiency via the replacement of dated legacy photomultiplier tubes with silicon chips.

This advanced technology allows for hyper accurate radiation detection, improved human factors, and greater ruggedization. We believe it will redefine industry standards in operational productivity and reliability. Lastly, we announced our next generation Apex Guard software application. This digital platform incorporates more comprehensive reporting and improved analytics to drive greater workplace efficiency and inferential reliability. This is particularly relevant for the exploding nuclear medicine sector. These product releases are emblematic of our focus on delivering innovations to meet customers’ growing needs. We are also broadening our nuclear power portfolio through M&A. Yesterday we announced the acquisition of Survalent, shown on Panel 7. Approximately 55% of Survalent’s revenue comes from nuclear power customers, including the operating fleet, new utility scale projects, and small modular reactors. Today, every U.S. nuclear reactor facility employs at least one Survalent solution.

Survalent’s business has grown double digits since 2022, and we believe we can enhance that growth with commercial synergies enabled by our vast global network. As previously mentioned, nuclear power operators are looking to extend operating lifetimes and expand existing nuclear reactor capacity. Survalent solutions help support these objectives by streamlining the regulatory burden. Survalent’s solution set is also relevant to the SMR sector. Today there are approximately 127 SMR designs globally, each trying to navigate a complex and burdensome regulatory environment. Survalent’s leading position in this space means they will likely benefit regardless of which SMR technologies ultimately prevail. The other 45% of Survalent’s revenue comes from the bulk electric system, generally referred to as the grid. This industry is regulated by the North American Electric Reliability Corporation, or NERC, and includes power generating assets above 20 megawatts connected to the power grid.

Until recently, this threshold was 75 megawatts. This is an important distinction as this regulatory change expands the number of assets under NERC’s purview by approximately 65%. This represents an additional revenue opportunity for Survalent. In short, this is a fast growing market in which Survalent is extremely well positioned. We look forward to growing our presence in this space. With that, let me turn it over to Brian to discuss the quarter and 2025 guidance. Brian, thank you Tom, and good morning everyone.

Brian Schopfer, CFO and Medical Group President, Mirion Technologies: I’ll pick up on Slide 8 with details on our second quarter order performance. Orders grew 1.6% in the quarter, driven by our Medical segment. Nuclear and Safety orders were lower year over year due to a tough prior year comp from the nuclear power vertical. Nuclear power related orders increased 17% in the second quarter last year. These orders can be a little lumpy, and we’re expecting an accelerated order book in the second half of the year based upon our current pipeline. Still, year to date nuclear power orders grew 10%, reflecting the growing momentum in this attractive end market. We are definitely seeing good momentum in the North American and French nuclear power installed base. As Tom discussed, SMR related activity continues to accelerate. We are highly engaged with key SMR players to support their journey to commercialization.

This is a rapidly evolving area, and we’re excited to be squarely in the mix. On the Medical side, all three end markets, RTQA, Nuclear Medicine, and Asymmetry, saw order growth in the quarter. This dynamic is particularly impressive in Nuclear Medicine, where we are lapping a 16% organic order increase in the second quarter of 2024. Slide 9 provides an update on the large one-time 2025 order pipeline that we’ve discussed over the past few quarters. This pipeline is bigger than what we’ve seen in the past years and indicative of the tailwinds across key end markets. Today, our pipeline stands at approximately $350 million. We continue to believe we will win our fair share of opportunity set in play. Encouragingly, the project pipeline for 2026 continues to build, and we like our competitive positionings a lot.

Moving to the financial results on Slide 10, second quarter consolidated revenue was $222.9 million, up 7.6% versus Q2 2024. Organic revenue grew 5.4% over the same time period. As expected, FX was a positive contributor to revenue growth given the weaker U.S. dollar environment versus the Euro. Within the Nuclear and Safety segment, we saw organic revenue growth across each end market. The nuclear power installed base revenue growth was the largest driver in the segment, reinforcing the importance of this sector to our growth expectations. In the Medical segment, organic revenue grew across all three medical end markets. Adjusted EBITDA grew as well, up 4.9% to $51.2 million. While adjusted EBITDA dollars grew, margins contracted slightly due to a couple of non-recurring items. In our Nuclear and Safety segment, we experienced FX-related transactional headwinds in France.

In addition, project cost increases for a nuclear project in the UK negatively impacted project margins in the second quarter. Lastly, on this slide, adjusted EPS was $0.11 per share, a 10% increase compared to last year. Note that this includes 17.3 million additional shares related to the convertible notes. If you exclude the convertible notes, the warrant redemptions in Q2 2024, and the founder shares that vested in late 2024, our adjusted EPS would have been $0.13. This provides a more apples-to-apples comparison. Regarding the convertible note shares, from a GAAP perspective, we’re required to use the fully diluted share count. You can see on slide 29 in the Appendix how the convertible and cap call structure impacts share count at certain share prices.

Most importantly, there is zero dilution until the share price approaches $35, and even at $60 per share, the effective dilution is approximately 40% of the GAAP number. Moving to the segments, beginning on slide 11, the Nuclear and Safety segment revenue grew 5.8% to $141.7 million. Organic revenue grew 2.9% in the quarter. Year to date, organic revenue grew 5.2% through the first half of the year. Labs and research has been softer than expected, reflecting delays and budget uncertainty confronting the U.S. Department of Energy as well as tariff uncertainty from China. More significantly, our nuclear power end market is exhibiting double-digit year-to-date revenue growth. Adjusted EBITDA declined slightly to $37.9 million, down 2.6% versus the second quarter last year. Adjusted EBITDA margins contracted in the quarter, reflecting a few non-recurring cost items we already discussed.

Moving next to the Medical segment on slide 12, segment revenue grew 10.9% to $81.2 million. Organic revenue grew 10.1% in the quarter. Revenue was $2 million higher due to some accelerated shipments, mostly in RTQA, to get ahead of expected tariff implementations early in the second quarter. This was partially offset by the lapping of our laser business closure. This will be the last quarter for a lasers business adjustment. If we normalize for these, each medical end market performed well in the quarter. Medical segment adjusted EBITDA was $30.1 million, up nearly 20% versus last year. Adjusted EBITDA margins increased approximately 280 basis points. This margin performance was in line with the expectations we shared on our first quarter earnings call. Margin improvement reflects the power of our intrinsic operating leverage we’ve been discussing. In addition, procurement and mix performance positively impacted margins in the quarter.

Let’s spend a few minutes on adjusted free cash flow on slide 13. We continue to improve adjusted free cash flow in the second quarter, adding another $6 million to end 1H25 with $35 million of adjusted free cash flow. Most importantly, we’re improving our conversion as well. Beyond higher earnings, the biggest drivers continue to be net working capital improvements, an optimized capital structure, and tight controls around CapEx. For instance, on net working capital, project cash flow management and improved collection performance contributed positively to the first half of the year. We continue to expect improved productivity in net working capital through year end within our capital structure. A lower SOFR rate environment over the past 12 months was a tailwind for interest expense, as was the debt refinancing we did in 2024.

Separately, we successfully launched a convertible note in the second quarter and amended and extended our existing term loan, pushing its maturity to 2032 and significantly reducing the principal amount. These actions will be more impactful in the back half of 2025 and fully reflected in 2026. Lastly, year to date, CapEx totaled $17 million, approximately $7 million lower than the first half of 2024. We’re on track for 2025 CapEx of $40 million and an 18% reduction versus 2024. Before we open the call to Q&A, slide 14 details our updated 2025 guidance. We have raised and tightened key 2025 metrics including total revenue growth, adjusted EBITDA, adjusted free cash flow, and adjusted EPS. We slightly lowered organic revenue growth, but most importantly we raised organic revenue growth within the nuclear power end market. Let’s get into the details.

Moving top to bottom on the slide, organic revenue growth was revised lower to reflect U.S. Government budgetary headwinds impacting our labs and research business we already discussed. Recall that this end market within our nuclear and safety segment includes business from the U.S. Department of Energy and universities. As a result, we lowered labs and research expectations from low single-digit organic revenue growth to modestly negative growth in the end market. These reductions are being largely offset by increased organic growth expectations from our nuclear power end market. We now expect 2025 double-digit organic growth from nuclear power versus high single-digit previously. Next, total revenue growth is expected to be 7% to 9%, up from 5% to 7% previously. This reflects a 125 basis point tailwind for foreign exchange and a 100 basis point improvement from the acquisition of Survalent.

These tailwinds more than offset the slight adjustment to 2025 organic revenue growth. Adjusted EBITDA is now expected to be between $223 million and $233 million, up from $215 million to $230 million. This reflects the previously mentioned revenue drivers as well as revised cost inputs from tariffs and foreign exchange. Adjusted free cash flow is forecasted at $95 million to $115 million, representing both an increase to total dollars and conversion rate. The increase reflects higher expected EBITDA, lower cash taxes, and net interest expense savings. Project cash flow timing in the second half will likely cause net working capital to be a use of cash for the full year. Lastly, adjusted EPS is expected to be between $0.48 and $0.52 per share and reflects the full GAAP impact of the additional shares related to the convertible note.

We’ve included in the appendix a slide that illustrates changes to 2025 guidance over the past four disclosures. For the third quarter, we’re expecting Nuclear and Safety segment adjusted EBITDA margins to be flattish year over year before rebounding nicely in our seasonally strong fourth quarter. In our Medical segment, adjusted EBITDA margins should show slight year over year expansion. Medical segment organic revenue growth should return to mid-single digits, accounting for the shipment timing of sales volumes related to potential tariff impacts in the second quarter. With that, we’re happy to take your questions.

Stacy, Conference Call Operator: Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press Star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press Star two to remove yourself from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Your first question comes from Chris Moore with CJS Securities. Please go ahead.

Hey, good morning, guys.

Tom Logan, Chairman and CEO, Mirion Technologies: Thanks for taking a couple.

Good morning.

Maybe just start on the new nuke side.

It takes, you know, many.

Years to get a new nuclear plant.

From concept to energy production, can you at all quantify the number?

Of new opportunities you’re looking at now, say versus two years ago? Yeah, I mean, broadly speaking, Chris, what I would tell you is that both the quantum of new projects and the desired timing of those projects continues to accelerate. I think historically we have touted the strategic alliance we forged with EDF in France that could span well over 20 years and cover all of their new EPR reactors, of which many are planned for France, the balance of Europe, and other parts of the world. We’re encouraged of late by what’s happening here in the U.S. I think if we had been having this conversation certainly two years ago, even a year ago, we still would have been skeptical about the prospects for new utility scale nuclear in the U.S.

Right now it is being openly discussed that Westinghouse, one of the leaders in the global reactor design space, is talking about up to 10 new AP1000 reactors in the U.S. with starts prior to 2030. This is very encouraging. Again, it’s kind of the tip of the iceberg because you have to go well beyond utility scale, well beyond Westinghouse and EDF, and look at the many other players globally, the Russian firm Rosatom, the Koreans, certainly the Chinese, all players in that utility scale space. On top of that, you again have this array of SMR players, the 127 discrete projects that we talked about.

What’s happening today that may be a little bit different is that not only are we seeing an accelerating pathway, just driven by the extreme urgency caused by this AI-catalyzed shortage of electrical power, but also caused by meaningful shifts in policy stance, particularly in the U.S., is that people are moving faster and more deliberately and with greater confidence. As a consequence, right now we are engaged in many strategic discussions that go beyond simply project-related or transactionally oriented deals to frame agreements where all of the major players are looking to consolidate supply chains, link up with strategic partners that can really carry them through the next decade and beyond. This is what I’m more excited about than anything in this space. The magnitude and the intensity of the activity here is enervating. I’m not going to give you a specific number.

I would tell you that the quantum is growing, timelines are accelerating, and I think the tangibility of what’s there continues to solidify. We’re pretty fired up about this.

Brian Schopfer, CFO and Medical Group President, Mirion Technologies: Really helpful.

Tom Logan, Chairman and CEO, Mirion Technologies: Maybe just a follow up. Could you talk a little more about the Survalent acquisition, how it fits in with the core business and synergies, why you’re so excited. Yeah, Survalent is an unbelievable company. Its founder led, Ted Enos, built the business and has run it throughout its lifetime. It really is a unique asset that today really defines the space that they’re in. We touched on some of the key financial metrics in terms of how it’s performing. $17 million in revenue, very, very attractive margin profile, incredible customer retention, 110% net revenue retention overall. Their platform includes 15 different SaaS applications and they play today within a total addressable market that’s just shy of $900 million. What’s also very, very interesting about Survalent is that they possess 15 terabytes of unique industry data, which is an extraordinary number overall.

I think it’s self-evident to everybody that when you think about the AI potential that that represents not only in terms of further streamlining their core software and services delivery today, but also what it means in terms of streamlining and accelerating regulatory approval processes, that is incredibly attractive and one of perhaps the less visible assets with us. The attractiveness to us firstly is that the majority of their revenue is in nuclear power. This year about 50% of the revenue will come from the installed base. About 6% will come from nuclear new builds. This is obviously core to our strategic focus right now. We love it because again recurring revenue, SaaS based software, massive, massive, massive AI potential here.

On top of that, the other 42% of the business, this NERC FERC business that extends to the broader electrical grid is also relevant and important to us overall. Fundamentally, when you look at the value proposition that Survalent brings to bear, at their core the problems they’re trying to solve, the customer pain points are that today, absent a solution like theirs, there’s significant risk of human error. There is an immense volume of complex standards to track, to understand and to apply. You have a situation where industry experts that really have the legacy knowledge are retiring and insufficient expertise is a real threat on the customer side.

The solution that Survalent offers essentially is the ability for their customers to outsource non-core mission critical functions to decrease the risk of license revocation, fines, etc., to increase communication efficiency with regulators, and fundamentally to ensure grid continuity, sufficiency, and security. We’re excited about it, firstly because it fits squarely within our focus on nuclear power delivery. It fits squarely within our focus on continuing the digital evolution, and particularly the AI-enabled digital revolution that’s taking place in our various markets. Finally, working together with the Survalent team, we think there is a huge opportunity for us to tap into our vast commercial network to provide them stronger and more efficient infrastructure. Again, recognizing their margin profile and their incredible capabilities as a team, we think this is going to be a great asset for us overall. Perfect.

Brian Schopfer, CFO and Medical Group President, Mirion Technologies: I will leave it there.

Tom Logan, Chairman and CEO, Mirion Technologies: Thanks guys.

Stacy, Conference Call Operator: Next question, Joe Ritchie with Goldman Sachs & Co. LLC, please. Go ahead.

Guys.

Brian Schopfer, CFO and Medical Group President, Mirion Technologies: Joe.

Tom Logan, Chairman and CEO, Mirion Technologies: Yeah, my first question, look, it.

Was good to see the nuclear power growth rate raised for the year. I guess if I go back to Slide 5, right, you talk about like 80% of your revenue coming from your installed base. I know this is simplistic, but should we be thinking about kind of like, I don’t know, eight points of growth coming from the installed base this year. What I’m really trying to get at is you talked about extensively having conversations with your customers. I think what I’m trying to figure out, and I think what investors are trying to figure out, is how bankable is the growth rate from the installed base, not just this year, but really, really beyond this year.

Yeah, and here, Joe, we have to approach it axiomatically because the dynamics are changing rapidly and broadly. The key fundamentals here are that, A, there is insufficient electrical generating capacity globally to support current needs and those needs continue to grow at a very high rate, again based upon the work of hyperscalers in support of AI overall. Secondly, policy shifts clearly have favored nuclear power, not just in the U.S. but around the world. Market dynamics have adjusted to make nuclear power plants very. Fundamentally, over what has been about a five year period, we have seen a shift from kind of tepid fundamentals in that market to very, very strong fundamentals. Recognizing that over the last 20 plus years this has been a tough market, over much of that time, nuclear power stations were losing money and many were targeted for early decommissioning.

As a consequence, we have a buildup of underinvestment in those power plants where people were operating under extreme capital rationing modes. The first thing that’s happening is that as we see capital budgets swelling, operators are investing in current infrastructure to modernize it, bring it back up to snuff, and then to prepare for the things that we touched on, which is the broader modernization, trying to operate plants at higher capacity factors, contemplating up rates and life extensions across the board. Not only does this reverse that dynamic of extreme capital rationing, but it also over time is shifting their footing toward more growth capital to enable these things. Those are the fundamentals that are essentially underpinning the overall operating fleet.

At the end of the day, when you look at the broad array of solutions, not just instrumentation, but software, and now with the VITAL platform, VITAL enabled software and services, the fundamentals are like nothing that we have seen literally in a generation. From our standpoint, as we look at this, while we’re not going to quantify a specific number in terms of longer term growth rates in the space, clearly it is moving up and to the right. Our expectation is that this is a generational trend that we’re going to work very, very hard to exploit continuously, maybe just one, you.

Brian Schopfer, CFO and Medical Group President, Mirion Technologies: know, added color without giving you the exact numbers. Joe, you know, one of the things I pointed out in my commentary is, you know, we saw, we’ve seen year to date good growth out of both North America and France. These are both installed base markets for us today. I think we’re encouraged by the new build opportunities in both markets with what EDF’s announced in France and Tom’s comments on Westinghouse. Today they’re basically installed base markets for us. I think you can read that as you will.

No, that’s helpful. Qualitative color, guys, I guess shifting to orders and the $350 million pipeline that you guys have discussed, I fully recognize also the second quarter you guys had a tough comp.

I guess what we’re trying to understand.

Has the $350 million kind of pushed to the right a little bit? Is the opportunity still substantial into the second half of the year? I guess specifically, I’m going to go back to numbers, but could there be a quarter where you guys see, you know, like a $300 million plus order quarter because of this large opportunity that you have?

Tom Logan, Chairman and CEO, Mirion Technologies: I think we’re unlikely to see a $300 million order quarter. Having said that, as Brian said, we like where we sit in this opportunity set overall. Some of it has shifted to the right, mainly the government related stuff because of budgetary uncertainty. There is some possibility that given the government year end at the end of September, we may see a little bit of more accelerated order intake in that sector overall. Bear in mind that when you look at the composition of what’s in there, it is government related and new project related in the main. There’s always some risk of timing slippage in these arenas. What we’ve said is that we expect to win our fair share of this. Again, we like where we sit today, can’t control the timing.

Bear in mind that these are large orders that we have called out to go above and beyond the core flow orders in the business. Ultimately, we do expect to monetize a decent chunk of this.

Brian Schopfer, CFO and Medical Group President, Mirion Technologies: I think the other, maybe a couple things is, one, it’s been a fairly consistent number. This quarter we gave a number versus a range just because we felt like that was more appropriate. Two, I made this comment a quarter ago. Things have moved in and out. New things have come in, other things have moved out. I think that’s actually encouraging, not discouraging. I also would tell you we like what we’re seeing in 2026 on some of these larger projects. We haven’t decided if we’re going to quantify kind of what those numbers look like. I would say the 2026 pipeline on larger deals continues to build, and every week and every month there’s new stuff kind of being added.

Timing kind of continues to be a little bit the wild card, but we continue to talk about it, which means we continue to feel pretty good about it.

Got it. If I could just sneak in one more for you, Brian. Just the margins on nuclear and safety and specifically the project cost increase in France, understand, like the FX transactional piece of the issue. What I’m trying to understand is whether there is kind of like a lingering margin issue or cost issue associated with that project that maybe kind of, you know, hampers margins through the rest of the year. I’m just trying to understand, like the.

Tom Logan, Chairman and CEO, Mirion Technologies: The implications of it.

Brian Schopfer, CFO and Medical Group President, Mirion Technologies: No, the challenge with just the accounting of the large projects is, you know, if you’re significantly way through the project and there’s some costs that come, you have to take a significant amount of that cost all at one time in a quarter. It just shows up weird in a quarter as you’re truing those things up, Joe, you know, less, you know, more than we’re worried about project margins. This project actually will end up with kind of margin rates we expected when we started the project that’s ebbed and flowed over the five plus years that we’ve been executing on it. We are super proud of the team at France. We’ve seen just an amazing kind of up and to the right out of that business since two years ago.

We have a lot of confidence in everything they’re doing and we’re excited about both the operational and the commercial direction that’s happening in Europe more than probably as much as anywhere else, candidly, and in some instances more so. I think we’re making great progress operationally and I think you’ll continue to see that in the numbers. I would tell you we’re not backing off our 30% number. We’re still very squarely committed to that by 2028.

Stacy, Conference Call Operator: Next question. Andy Kaplowitz with Citigroup, please go ahead.

Hey, good morning, everyone.

Tom Logan, Chairman and CEO, Mirion Technologies: Morning, Andy.

Brian Schopfer, CFO and Medical Group President, Mirion Technologies: Good morning, Andy.

Maybe I’ll try Joe’s question in a slightly different way. If we’re sitting here at the end of the year, would you be quite disappointed if your backlog, or at least your commercial nuclear backlog, isn’t higher than it is today?

Tom Logan, Chairman and CEO, Mirion Technologies: I think we would, yeah. Given what we’re seeing, Andy, that would be a surprise to all of us. The short answer is yes, we would be disappointed.

Easy enough. Tom, maybe just the SMR orders, obviously they’re still kind of small numbers, but there’s obviously a ton of noise around SMR lately, as you kind of pointed out. Do SMR orders become a more meaningful part of your order ramp up, even over the next six to twelve months, like we all kind of thought it was next decade? It does seem like there’s some real activity here over the next few years. Does it become meaningful faster now, at least in the order profile?

Andy, we continue to be cautious here. Again, recognizing that this is an industry, a space, a sector that will go through some level of consolidation. Clearly, we’re not going to have 127 viable SMR players 10 years from now. We expect that right now as we kind of churn through this wave of first-of-a-kind reactors, this is the time when strategic alliances are being forged. We’re working hard to make sure that we get our fair share or better of positioning in the leading players in the space. Overall, clearly it has accelerated faster than I would have guessed a year ago. We like the cadence of what we’re seeing. We love the engagement that we’re enjoying right now, experiencing with these players, but we’re going to continue to be cautious about this.

We’ve got to get through first-of-a-kind, see how those work out, and where the real growth begins is when you then get into the broader proliferation and extension of those, the first-of-a-kind type. We continue to be cautious. We’re happy that we are seeing an acceleration, but I’m not going to call for some dramatic spike above and beyond where we are helpful.

Tom, and then maybe given concern about hospital reimbursement, you mentioned Doug. It’s obviously not surprising they’re seeing, you know, some modest impact on their end. Maybe you could talk about the resiliency of your medical and lab businesses moving forward, that you won’t see incremental sort of negative revisions to your growth forecast. I mean, is this kind of you adjust and then you move forward in medical overall, still, you know, call it a mid single digit plus business.

Yeah, this is an area where I think we’ve highlighted over the last three quarters that we’re watching this. Clearly, there is a lot of battlefield haze right now within the medical community overall just given the uncertainty around budgetary dynamics. That was a part of that certainly in the recent and tax bill. The cutbacks to Medicaid are a part of that overall. We have been pushing the team very, very hard for the better part of the last year to give us the best possible insights in and around this market and really to be looking around corners for signs of what you articulated. What we’re seeing so far is that our markets have held up pretty well in part because radiation therapy in general tends to have a higher proportion of reimbursement dollars coming from Medicare versus Medicaid and from private insurance overall.

Secondly, given the imperative to improve efficiency within radiation therapy clinics, that plays well with our solution set. Our product offerings are all about efficiency and accuracy and help drive greater patient throughput in these facilities. The central part of that is our SunCHECK software platform, which at its heart is a workflow platform that drives great efficiency in that environment. On top of that, it’s all of our hardware applications that in a very efficient fashion across different RT platforms, not just Varian but Elekta and others, help support that kind of efficiency. To be clear, we continue to be very watchful around this market and the dynamics. We are pushing the team hard to give us any early signs that there may be a change or an erosion in the rate of growth. I would tell you that today we have not seen that as of yet.

Stacy, Conference Call Operator: Next question comes from Yanzi with B. Riley Securities. Please go ahead.

Good morning.

Brian Schopfer, CFO and Medical Group President, Mirion Technologies: Thank you for taking our questions. Can you help us understand the current supply and demand dynamic with your nuclear medicine customers?

Are they sensitive to pricing due to the current bonding status, or is the.

Demand growing much faster than the supply right now?

Tom Logan, Chairman and CEO, Mirion Technologies: Yeah, Yuan, what I would say is that if you look at it, there are really two components associated with our nuclear medicine business. One is kind of our core hardware offerings where the franchise product there would be dose calibration instruments and above and beyond that is clinical instruments and transport equipment, compounding equipment, syringe shields and the like. Really think of dose calibration instruments as being the bellwether. The second major component is our software platform, our EC2 software platform, which uniquely is connecting drug makers and isotope producers and CDMOs and radiopharmacies and clinics. When we look at the overall growth rates and the demand that we’re seeing, we do like our positioning.

If you look at the margin profile of this business overall, it continues to improve, which is emblematic of a combination of both pricing power as well as the fact that we are mixing up in this space principally through a higher proportion of software sales overall. The fundamentals here continue to be tracking with our expectations that they’re, as you know, better than most. The theranostic movement, the theranostic revolution is real and we’re seeing a lot of activity in and around that. Our view is that if the trends continue as we believe they will, that will continue to drive margin accretion in our business and support the kind of longer term growth that we’ve called for.

Brian Schopfer, CFO and Medical Group President, Mirion Technologies: Got it. Thanks for the helpful color there. It’s also great to see the strong Mirion backlog growth in 2025. Sorry, I have to ask Andy’s question.

In a slightly different way.

If we exclude SMRs in the order.

Books in both 2Q 2024 and 2Q 2025, what is the growth from the.

Conventional nuclear power in the order book? I gotta see if I have the data in front of me. If you look at it from a quarter or year to date perspective, I would tell you that we are—sorry, I got the wrong page, apologies. If you look at it from a year to date perspective, we still have positive.

Tom Logan, Chairman and CEO, Mirion Technologies: Order.

Brian Schopfer, CFO and Medical Group President, Mirion Technologies: Growth in the nuclear power segment. You got to be a little bit careful kind of trying to parse things in and out here because of the lumpiness of some of the orders, which is why I don’t want to give a precise number because at the end of the day, you know, that could change with when we win a large order in the third or fourth quarter. You know, we still feel very good about the order dynamics even if you exclude the larger SMR order that we’re seeing kind of in the underlying base. Most importantly, I mean our revenue numbers are double digits. I would tell you that with very little SMR revenue running through the P&L today. That is, I think, the most encouraging thing. Yep, got it. Thank you.

Stacy, Conference Call Operator: Next question. Rob Mason with Baird, please go ahead.

Yeah, good morning. Thanks for taking the question, Tom. I wanted to go back to your conversation around the installed base and nuclear power, where you talked about the larger buckets of opportunities. You mentioned life extensions, perhaps the largest opportunity for Mirion. Is there a sort of more quantitative way that we can think about that? You’ve been helpful in the past talking about content per reactor on new builds, maybe on a per megawatt basis. I’m sure there’s much more variability around life extensions, but is there a metric that we can think about to properly size what that opportunity could be?

Tom Logan, Chairman and CEO, Mirion Technologies: Rob, we’ve not guided a specific metric because this is something that can vary depending on the type of reactor. Is it a pressurized water reactor? Is it a boiling water reactor? Is it a heavy water reactor? There’s variability in and around all of those things. To some degree, there’s also variability induced by the size of the fleet. If you look at somebody like Constellation, the number one operator of nuclear power plants in the U.S. versus others who may be operating a single power plant, it varies depending on how those fleets are being managed overall. What we have said and what I would reiterate here is that when you are looking at a life extension event, typically that is a trigger for a higher degree of modernization CapEx relating not only to instrumentation but also to software.

This is where there are certain product categories like radiation monitoring systems, which typically have about a 20-year replacement cycle, give or take a few years, depending on facts and circumstances. Oftentimes when an operator is making a decision to life extend a power plant, that’s when they’ll say, okay, we need to upgrade our core RMS systems. It varies across the board. I’m hesitant to give you any specific guidance on, you know, the numbers are in this range and you can put that into your model.

Sure.

During the quarter you did announce the partnership with Westinghouse around some of your instrumentation in particular. My sense was historically that fleet, Westinghouse fleet, you had not had as high a representation there. Am I right in thinking about this is more around potential share gain on top of replacement activity for you within that fleet? Is there any way to put some broader numbers around what that opportunity could be?

Yeah, that’s 100% accurate, that this is an opportunity to essentially upgrade the fleet that Westinghouse covers with a digital neutron flux measurement system. These instruments, just for the uninitiated, are essentially measuring a variety of parameters inside the reactor core and immediately outside of the reactor core, the most important of which is neutron flux, which is essentially the volume of neutrons that pass through a defined volume in a given period of time. It’s essential to understand those dynamics because that provides a lot of insights about the operating quality and the safety of the combustion that’s taking place inside that reactor. Overall, our digital solution is unique. Westinghouse obviously sees it as a great opportunity in their broader service and maintenance business to utilize this as a, as you know, kind of a core offering in upgrading reactors.

Overall, we see a sizable opportunity to retrofit the installed base within the U.S. and, you know, more broadly, not just through the Westinghouse deal, to leverage this technology on a global basis overall. In our view, this is an opportunity for share pickup. It’s not merely replacing our legacy products with something newer and better. Very good.

Maybe just last question, Brian, in talking about the margin expansion, I guess in Medical, you mentioned procurement is one of the contributors and that was obviously something that was part of the algorithm and that you unveiled at the investor day around 20-30% margins. Could you just update us more broadly where you are in that effort relative to, I guess, the target that you issued at that time? How should we think about just phasing in of that procurement?

Brian Schopfer, CFO and Medical Group President, Mirion Technologies: Like I think I said to Joe, I think we’re still very committed to the 30% EBITDA margin target. Obviously this year our guide still indicates kind of more than 100 basis points of margin expansion. That’s our expectation. Obviously that means it needs to pick up from here. That’s what we’re very focused on. Even an acquisition like Survalent, although not contemplated, then helps with this journey. They actually have better EBITDA margins than we do as a company. That’s helpful. I think we’re still, I know we’re still, we’re still very committed to it. The idea generation and the tactical pipeline is still very robust. We like what we’re doing on the procurement side.

One of the things that we’ve announced internally and we should talk about it a little bit here is some of the variabilization of both our software and IT labor in a partnership deal we did with a large partner in this space called Cognizant that we’re super excited about. We think it will add a ton of value for us both on the cost side, but actually even more importantly on the speed to market side for new software products. That’s something that we continue to implement here over the next couple quarters. We feel good. I think one of the things you saw in the medical space this quarter is just that operating leverage. I mean when you get into these high single digit and in this case double digit kind of quarters, the P&L structure really plays to our favor specifically in that business.

And.

We saw 200 basis point margin expansion across every one of the businesses we have within our Medical business in the second quarter. We’re excited about where we’re going.

Tom Logan, Chairman and CEO, Mirion Technologies: We’Re even.

Brian Schopfer, CFO and Medical Group President, Mirion Technologies: I would tell you we continue to have a lot of conviction around our targets.

Tom Logan, Chairman and CEO, Mirion Technologies: Yeah, Rob, just to tag on to Brian’s comments too. Historically, we’ve been very clear that the pathway to 30% margins is a combination of operating leverage, which is the biggest single lever. That’s what’s carried us historically. It’s price, it’s procurement, it is continued footprint rationalization. It’s the fact that with our clear focus on digital, we expect that we’re going to continue to mix up overall from a margin standpoint. There’s something new that’s emerging here that I think is worth touching on and that’s AI. In this recent announcement where I’ve stepped away from running the Medical Group, Brian has picked that up. A major factor behind that is that I’m dedicating a substantial proportion of my cycles, if you will, toward AI. We see two enormous opportunity sets in that regard. One is internal, where part of it is the future of work.

I know that today a third or more of my job can be done better with AI and independent autonomous agents than I can do it personally. I know that to be true for just about every non-shop floor position within our business. We know that AI represents not in the future but today an opportunity for us to substantially improve not only our efficiency but also our net output capabilities from a human capital standpoint. Additionally, internally there are more and more near-term opportunities to harness AI for supply chain management, for conversion activities. Think of it in terms of master production scheduling, for distribution capabilities, for product design capabilities, et cetera. We’re in the process of really winnowing our hierarchy of priorities to make sure that we’re getting after this aggressively.

The second bigger bucket is the customer-facing stuff where clearly we see enormous opportunities to improve the utility that we are bringing to our customers through AI solutions. We’re taking this very seriously, devoting substantial resources to it. All of this, at the end of the day, when you come back to the margin equation, is an additive factor to what we’ve talked about historically.

Stacy, Conference Call Operator: Thank you. I would like to turn the floor over to Tom Logan for closing remarks.

Tom Logan, Chairman and CEO, Mirion Technologies: Thank you again for your time and attention today. We’re happy about the quarter. We feel like we continue to improve our financial metrics and our operating metrics. We continue to be very bullish about the order pipeline and expect to continue to extend the dynamics there in terms of what we bring down over the course of the year. We continue to enjoy the tailwinds that we see. There continues to be some noise in the market, in and around tariffs, global geopolitics, reimbursement dynamics, et cetera. Our view continues to be that the tailwinds beat the headwinds here. We like where we sit and feel good about how the economy and the year are unfolding. We appreciate your time and attention today and we’ll very much look forward to speaking with you again next quarter.

Stacy, Conference Call Operator: This concludes today’s teleconference. You may disconnect your lines at this time, and thank you for your participation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.